Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biosynex SA ( (FR:ALBIO) ) has provided an update.
BIOSYNEX SA announced the number of shares and voting rights as of February 28, 2025, with 18,748,031 shares and 22,531,235 voting rights. This information reflects the company’s current capital structure and may impact shareholder decisions and market perception, reinforcing BIOSYNEX’s transparency and regulatory compliance.
More about Biosynex SA
BIOSYNEX, founded in 2005, is a French laboratory specializing in health diagnostics, particularly in rapid tests, biotherapy monitoring, and molecular biology. The company focuses on innovative health solutions for laboratories, hospitals, doctors, and the general public, enhancing patient care. BIOSYNEX expanded internationally post-Covid-19, with subsidiaries in the US, Europe, and Asia, and offers a wide range of products through its BIOSYNEX PHARMACY and BIOSYNEX DIAGNOSTIC divisions.
YTD Price Performance: 33.02%
Average Trading Volume: 344
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €26.99M
For an in-depth examination of ALBIO stock, go to TipRanks’ Stock Analysis page.